Loading...
 
Translate Register Log In Login with facebookLogin and Register

Diabetes not treated by 28,000 IU of weekly vitamin D (proven again) – RCT Sept 2016

Effect of vitamin D supplementation on oral glucose tolerance in individuals with low vitamin D status and increased risk for developing type 2 diabetes (EVIDENCE): a double-blind, randomized, placebo-controlled clinical trial

Diabetes, Obesity and Metabolism DOI: 10.1111/dom.12794
Tracy S Moreira-Lucas tracy.moreira at mail.utoronto.ca, Alison M Duncan, Remi Rabasa-Lhoret, Reinhold Vieth, Alison L Gibbs, Alaa Badawi, Thomas MS Wolever

See also VitaminDWiki


Aims: Low serum 25-hydroxyvitamin-D [25(OH)D] concentrations are associated with insulin resistance, β-cell dysfunction and type 2 diabetes. We conducted a 24-week double-blind, randomized, placebo-controlled trial to examine the effect of 28 000 IU of vitamin D3 once weekly on plasma glucose after a 2h-75g oral glucose tolerance test (2hrPC glucose), insulin sensitivity and β-cell function.

Design: Seventy-one participants with serum 25(OH)D ?65 nmol/L, impaired fasting glucose, and elevated glycated hemoglobin were randomly assigned to receive 28 000 IU of vitamin D3 (VitD; n = 35) or placebo (n = 36) in cheese once weekly for 24 weeks. The primary outcome was the change in 2hPC glucose. Secondary outcomes were fasting glucose, fasting and postprandial insulin, indices of insulin sensitivity and β–cell function, glycated hemoglobin and lipid profile. Participants underwent an oral glucose tolerance test to determine 2hPC glucose.

Results: Mean baseline serum 25(OH)D was 48.1 and 47.6 nmol/L in the VitD and placebo groups, respectively. Serum 25(OH)D significantly increased to 98.7 nmol/L (51 nmol/L increase; P<0.0001) in the VitD group. No significant differences in fasting (P=0.36) or 2hPC glucose (P=0.56) or other indices of glucose metabolism, including β-cell function and insulin sensitivity were observed. A sub-group analysis of individuals with 25(OH)D <50 nmol/L and prediabetes did not change these results. The VitD group exhibited a significant reduction in LDL cholesterol (?0.27 vs. 0.01 mmol/L, P= 0.03).

Conclusion: Weekly doses of vitamin D3 in individuals with sub-optimal vitamin D and at risk for type 2 diabetes did not improve oral glucose tolerance or markers of glycemic status.

Clinical Trial Registration Number: Trial registered at clinicaltrials.gov, no. NCT01726777.

See any problem with this page? Report it (FINALLY WORKS)